SynthesisMedicina (Kaunas, Lithuania)2022
MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review.
Synthesis in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Assessment of Mitochondrial DNA Copy Number in Progressive Supranuclear Palsy Patients: Evidence From a Pilot Study.European journal of neurology · 2026Article
- RNA networks of lysosomal-related biomarkers in Parkinson's disease and their correlations with freezing of gait-associated genes.Frontiers in genetics · 2026Article
- Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.Journal of neurology · 2025Review
- An Exploratory Analysis of Differential Tear Fluid miRNAs in Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.Molecular neurobiology · 2025Article
- Fluid biomarkers in atypical Parkinsonism: current state and future perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Abnormal structural‒functional coupling patterning in progressive supranuclear palsy is associated with diverse gradients and histological features.Communications biology · 2024Article
- Progressive Supranuclear Palsy Syndrome: An Overview.IBRO neuroscience reports · 2024Review
- The potential of phosphorylated α-synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy.CNS neuroscience & therapeutics · 2024Review
- Role of microRNAs in cognitive decline related to COVID‑19 (Review).Experimental and therapeutic medicine · 2024Review
- Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges.Acta neuropathologica · 2023Review
- Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development.Medicina (Kaunas, Lithuania) · 2022Article
- Plasma microRNAs as a Potential Biomarker for Identification of Progressive Supranuclear Palsy.Diagnostics (Basel, Switzerland) · 2022Article
- Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.